Gemcitabine and docetaxel in metastatic sarcoma: Past, present, and future

Oncologist

Volumn 12, Issue 8, 2007, Pages 999-1006

  Maki, Robert G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Clinical trial; Docetaxel; Gemcitabine; Leiomyosarcoma; Sarcoma

Indexed keywords

CYTOTOXIC AGENT; DACARBAZINE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; GEMCITABINE TRIPHOSPHATE; IFOSFAMIDE; PACLITAXEL; PHOSPHOTRANSFERASE INHIBITOR; TAXANE DERIVATIVE;

CANCER CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; LUNG TOXICITY; MEDICAL LITERATURE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG SYNERGISM; HUMANS; SARCOMA; TAXOIDS;

EID: 34548461654     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-8-999     Document Type: Review

References (44)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Fury MG, Antonescu CR, Van Zee KJ et al. A 14-year retrospective review of angiosarcoma: Clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J 2005;11:241-247.
3. Grosso F, Demetri GD, Blay JY et al. Patterns of tumor response to trabectedin (ET743) in myxoid liposarcomas. J Clin Oncol 2006;24(suppl 18):9511.
4. Huygh G, Clement PM, Dumez H et al. Ecteinascidin-743: Evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients. Sarcoma 2006;2006:56282.
5. Fayette J, Coquard IR, Alberti L et al. ET-743: A novel agent with activity in soft-tissue sarcomas. Curr Opin Oncol 2006;18:347-353.
6. Le Cesne A, Blay JY, Judson I et al. Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005;23:576-584.
7. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature 1979;277:665-667.
8. Rowinsky EK, Onetto N, Canetta RM et al. Taxol: The first of the taxanes, an important new class of antitumor agents. Semin Oncol 1992;19:646-662.
9. Rowinsky EK, Donehower RC, Jones RJ et al. Microtubule changes and cytotoxicity in leukemic cell lines treated with Taxol. Cancer Res 1988;48:4093-4100.
10. Extra JM, Rousseau F, Bruno R et al. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 1993;53:1037-1042.
11. Rosing H, Lustig V, van Warmerdam LJ et al. Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion. Cancer Chemother Pharmacol 2000;45:213-218.
12. van Hoesel QG, Verweij J, Catimel G et al. Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 1994;5:539-542.
13. Verweij J, Lee SM, Ruka W et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults:Astudy of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000;18:2081-2086.
14. Isogai R, Kawada A, Aragane Y et al. Successful treatment of pulmonary metastasis and local recurrence of angiosarcoma with docetaxel. J Dermatol 2004;31:335-341.
15. Heinemann V, Hertel LW, Grindey GB et al. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-{beta}-D-arabinofuranosylcytosine. Cancer Res 1988;48:4024-4031.
16. Iwasaki H, Huang P, Keating MJ et al. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood 1997;90:270-278.
17. Gandhi V, Legha J, Chen F et al. Excision of 2′,2′- difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA. Cancer Res 1996;56:4453-4459.
18. Abbruzzese JL, Grunewald R, Weeks EA et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991;9:491-498.
19. Tempero M, Plunkett W, Ruiz Van Haperen V et al. Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003;21:3402-3408.
20. Patel SR, Gandhi V, Jenkins J et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 2001;19:3483-3489.
21. Merimsky O, Meller I, Kollender Y et al. Palliative effect of gemcitabine in osteosarcoma resistant to standard chemotherapy. Eur J Cancer 1998;34:1296-1297.
22. Amodio A, Carpano S, Manfredi C et al. [Gemcitabine in advanced stage soft tissue sarcoma: A phase II study.] La Clin Ter 1999;150:17-20. In Italian.
23. Merimsky O, Meller I, Flusser G et al. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: A phase II study. Cancer Chemother Pharmacol 2000;45:177-181.
24. Spath-Schwalbe E, Genvresse I, Koschuth A et al. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer drugs 2000;11:325-329.
25. Okuno S, Edmonson J, Mahoney M et al. Phase II trial of gemcitabine in advanced sarcomas. Cancer 2002;94:3225-3229.
26. Svancarova L, Blay JY, Judson IR et al. Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002;38:556-559.
27. Okuno S, Ryan LM, Edmonson JH et al. Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): A trial of the Eastern Cooperative Oncology Group. Cancer 2003;97:1969-1973.
28. Look KY, Sandler A, Blessing JA et al. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: A Gynecologic Oncology Group (GOG) study. Gynecol Oncol 2004;92:644-647.
29. Hartmann JT, Oechsle K, Huober J et al. An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Invest New Drugs 2006;24:249-253.
30. Von Burton G, Rankin C, Zalupski MM et al. Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma. Am J Clin Oncol 2006;29:59-61.
31. Wagner-Bohn A, Paulussen M, Vieira Pinheiro JP et al. Phase II study of gemcitabine in children with solid tumors of mesenchymal and embryonic origin. Anticancer Drugs 2006;17:859-864.
32. Smorenburg CH, Sparreboom A, Bontenbal M et al. Combination chemotherapy of the taxanes and antimetabolites: Its use and limitations. Eur J Cancer 2001;37:2310-2323.
33. Theodossiou C, Cook JA, Fisher J et al. Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines. Int J Oncol 1998;12:825-832.
34. Zoli W, Ricotti L, Dal Susino M et al. Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer. Br J Cancer 1999;81:609-615.
35. Leu KM, Ostruszka LJ, Shewach D et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 2004;22:1706-1712.
36. Dumez H, Louwerens M, Pawinsky A et al. The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors. Anticancer Drugs 2002;13:583-593.
37. Hensley ML, Maki R, Venkatraman E et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial. J Clin Oncol 2002;20:2824-2831.
38. Bay JO, Ray-Coquard I, Fayette J et al. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: A retrospective analysis. Int J Cancer 2006;119:706-711.
39. Thall PF, Wathen JK. Covariate-adjusted adaptive randomization in a sarcoma trial with multi-stage treatments. Stat Med 2005;24:1947-1964.
40. Thall PF, Wathen JK. Practical Bayesian adaptive randomisation in clinical trials. Eur J Cancer 2007;43:859-866.
41. Maki RG, Wathen JK, Patel SR et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft-tissue sarcomas. J Clin Oncol 2007;25:2755-2763.
42. Dunsford ML, Mead GM, Bateman AC et al. Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol 1999;10:943-947.
43. Azzoli CG, Miller VA, Ng KK et al. Gemcitabine-induced peripheral edema: Report on 15 cases and review of the literature. Am J Clin Oncol 2003;26:247-251.
44. Bramwell VHC, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev 2003;(3):CD003293.